INM (InMed Pharma) סך נכסי החברה

InMed Pharmaceuticals is developing a B2B segment for the synthesis of rare cannabinoids to combat glaucoma and neurodegeneration, aiming to expand its industry presence. The team of biochemists focuses on discovering new therapies for orphan diseases supported by stable financial backing. The historical price action of total assets reflects the value of 10.61. The firm's environmental profile is limited to basic waste utilization and office energy efficiency.

The scale of InMed Pharmaceuticals (INM) operations is reflected in the total asset value, which is reverse-calculated from the return on assets (ROA) to assess the total volume of resources required for diversifying research in dermatology and ophthalmology. Growth in this indicator confirms the expansion of the material base; however, it is critical for investors to correlate this with actual liquidity to avoid hidden imbalances in capital allocation across uncorrelated clinical projects.